Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01272245 · ClinicalTrials.gov registry record · Phase 2

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

A Phase 2 study of Leukemia, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT01272245: Completed Phase 2 study of Leukemia, sponsored by M.D. Anderson Cancer Center.

NCT01272245 is a Phase 2 study of Leukemia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01272245, a Phase 2 study of Leukemia, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if omacetaxine given with cytarabine can help to control the disease in patients with AML or high-risk MDS. The safety of the study drugs will also be studied.

Primary Outcome

Complete response (CR) defined as: Peripheral blood counts, no circulating blasts, neutrophil count ≥ 1.0 ×109/L, platelet count ≥ 100 ×109/L, bone marrow aspirate and biopsy, ≤5% blasts, no detectable auer rods, no extramedulary leukemia

Conditions Studied

Leukemia

Interventions

  • DRUG Cytarabine
  • DRUG Omacetaxine

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2011-07
Est. Completion 2017-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT01272245 record still lists

NCT01272245 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (93% lower).

The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Cytarabine is the first listed.

NCT01272245 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT01272245 about?

NCT01272245 is a clinical study titled "Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)". The goal of this clinical research study is to learn if omacetaxine given with cytarabine can help to control the disease in patients with AML or high-risk MDS. The safety of the study drugs will also be studied.

What is the current status of trial NCT01272245?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2011-07. Estimated completion is 2017-01.

What conditions does trial NCT01272245 study?

This clinical trial studies the following conditions: Leukemia.

What interventions are being tested in trial NCT01272245?

The interventions under investigation include: Cytarabine (DRUG), Omacetaxine (DRUG).

Who is sponsoring clinical trial NCT01272245?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01272245 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01272245's enrollment target sits among peer trials

36 146th of 233 higher than 86 of 233 other Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01272245, the US trial registry maintained by the National Library of Medicine. NCT01272245 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.